Business Wire

PA-BOOMI

Share
Boomi Celebrates Being Positioned Highest for Ability to Execute in the Gartner® Magic Quadrant™ for Integration Platform as a Service

BoomiTM, the intelligent integration and automation leader, today announced that Gartner has positioned Boomi as a Leader and placed the company highest for Ability to Execute in its Magic Quadrant for Integration Platform as a Service (iPaaS). This will be the tenth consecutive time Boomi has been named a Leader in the Gartner Magic Quadrant for iPaaS. Gartner evaluated 17 iPaaS providers on their Ability to Execute and Completeness of Vision.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240221163767/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Boomi Celebrates Being Positioned Highest for Ability to Execute in the Gartner® Magic Quadrant™ for Integration Platform as a Service (Graphic: Business Wire)

“We believe that being positioned highest for Ability to Execute and recognized as a 10x Leader in the Gartner Magic Quadrant for iPaaS underscores our unrelenting product excellence, innovation, and execution as a team,” said Steve Lucas, CEO at Boomi. “We are pushing the envelope further than ever before to bring groundbreaking innovations to market for the benefit of our customers and partners worldwide, and it is gratifying to see the industry take note of our considerable achievements.”

Trusted by more than 20,000 customers across all industries globally for its speed, ease-of-use, and lower total cost of ownership, the cloud-native, unified, low code, scalable, open, secure, and intelligent Boomi platform helps organizations quickly and easily accelerate business outcomes.

Boomi recently announced significant updates to its platform and business, including:

Product Innovation

  • Event Streams – Available through Boomi and in AWS Marketplace, the multi-tenant enterprise message queuing and streaming service allows organizations to create integrations that are more resilient, scalable, and real-time than traditional point-to-point integration processes.
  • Boomi AI – Leveraging deidentified metadata, patterns, and best practices from 200 million integrations made with the Boomi platform, Boomi AI offers a simplified user experience that harnesses generative AI to connect and integrate applications, data, processes, people, and things across organizations.
  • Boomi GPT – The first offering available in the Boomi AI suite, Boomi GPT brings a simple, conversational experience to the Boomi platform. With Boomi GPT, organizations can harness the power of generative AI to integrate and automate faster than ever before, further democratizing innovation and accelerating business outcomes.
  • AI Patents – This year Boomi achieved two new technology patents in the field of AI that challenge the existing paradigms inherent when constructing integration processes. These patents provide additional testament to the company’s innovation leadership and dedication of its talented team of engineers, scientists, and innovators.
  • New ISO Certifications – Boomi’s ISO 27001 and 27701 certifications demonstrate the company’s continued commitment to information security and privacy compliance. As one of the only iPaaS vendors that is also FedRAMP Authorized, Boomi is consistently evolving to ensure its compliance security and privacy programs continue to meet the stringent regulatory standards set by governments and its more than 20,000 worldwide customers.
  • StateRAMP Authorization – Achieving StateRAMP Authorization reflects Boomi’s unwavering commitment to data security and compliance, and to delivering a secure and reliable solution that government agencies can rely on to safeguard their data and operations.

Business Growth

As a category-leading, global software as a service (SaaS) company, Boomi touts a growing community of more than 100,000 members, and one of the largest arrays of global systems integrators (GSIs) in the iPaaS space. The company boasts a worldwide network of approximately 800 partners, and works with the largest hyperscaler cloud service providers.

Boomi has won numerous awards for product innovation and being an employer of choice, including being named to the 2024 list of Best Places to Work by Built In and the CRN Cloud 100 list for innovation in cloud-based technology development. In addition, Boomi has received the prestigious 5-star rating in the CRN Partner Program Guide for two consecutive years, was named a Fire Award honoree for innovation by the Philadelphia Business Journal and a Gold Stevie® Award winner in the American Business Awards for Company of the Year in 2023. Boomi has also been recognized by The Software Report as a Top 100 Software Company and for having one of the Top 50 SaaS CEOs.

To learn more, read the Gartner report: “Magic Quadrant for Integration Platform as a Service.”

Additional Resources

Gartner Disclaimer:

Gartner, Magic Quadrant for Integration Platform as a Service, Keith Guttridge, Andrew Comes, Shrey Pasricha, Max van den Berk, Andrew Humphreys, February 19, 2024

Boomi was recognized as Dell Boomi in 2014-2019. The report was previously titled as Magic Quadrant for Enterprise Integration Platform as a Service from 2017-2021 and in 2014. The report was titled as Magic Quadrant for Enterprise Integration Platform as a Service, Worldwide in 2015 & 2016 and as Magic Quadrant for Integration Platform as a Service, Worldwide in 2023.

Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Note: Boomi was recognized as Dell Boomi from 2014 to 2019.

About Boomi

Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.

© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240221163767/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models5.1.2026 14:54:00 CET | Press release

Falcon H1R 7B Packs Advanced Reasoning into a Compact 7 Billion Parameter Model Optimized for Speed and Efficiency TII’s Latest AI Model Outperforms Larger Rivals from Microsoft, Alibaba, and NVIDIA on Key Benchmarks The Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has announced the release of Falcon H1R 7B, a next-generation AI model that takes a significant step toward making advanced AI more accessible than ever, by delivering world-class reasoning performance in a compact, efficient, and openly available format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105981339/en/ TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models (Graphic: AETOSWire) With just 7 billion parameters, Falcon H1R 7B challenges and, in many cases, outperforms larger open-source AI models from around the world, including models fr

Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release

Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu

HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release

Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release

- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o

SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye